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Intravenous glucocorticoids provide no 
additional benefit over oral glucocorticoids 
in chronic obstructive pulmonary disease 
exacerbation 
ALEXANDER C. WASELEWSKI, Wayne State University School of Medicine, awaselew@med.wayne.edu  
 
ABSTRACT A critical appraisal and clinical application of de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den 
Berg JW. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest. 
2007;132(6):1741-1747. doi: 10.1378/chest.07-0208. 
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Clinical Context 
JB is a 68-year-old African American male with significant past medical history of chronic obstructive pulmonary 
disease (COPD) requiring 4 L of home oxygen. He has a 30.5 pack year smoking history, type II diabetes mellitus, 
and hypertension. He presented to the hospital with severe dyspnea and a positive respiratory syncytial virus 
polymerase chain reaction. He has been hospitalized numerous times in the past for COPD exacerbations most 
recently in the prior week. His GOLD score was 3 with a forced expiratory volume in the first second 36% of 
predicted. His wishes were to be treated to the full extent possible telling the team he wanted to go home. His 
venous blood gas showed a pCO2 of 76.7mmHg and a pH of 6.97 which required admission to the intensive care 
unit and bi-level positive airway pressure. The patient was started on ipratropium-albuterol nebulizers and 
completed a 5-day course of 40mg oral prednisone, a standard regimen in COPD exacerbations to prevent 
readmission and escalation of care.1 He showed no improvement and the team decided to try intravenous (IV) 
methylprednisolone, which did not help either. Intravenous (IV) methylprednisolone was tried because he was 
clinically deteriorating, and the team wanted to avoid mechanical ventilation. 
Clinical Question 
Do IV glucocorticoids have lower rates of treatment failure regarding COPD exacerbations compared to oral glucocorticoids? 
Research Article 
de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV prednisolone in the treatment of COPD 
exacerbations: a randomized, controlled, double-blind study. Chest. 2007;132(6):1741-1747. doi: 10.1378/chest.07-0208 
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Related Literature 
To begin the search for articles, PubMed was used with the search phrase, “IV glucocorticoids COPD exacerbation;” 11 relevant 
articles were selected after reviewing the abstracts. Additionally, UpToDate was searched using “COPD exacerbation treatment,” 
and references browsed for articles not already found through PubMed. PubMed was again searched using the terms, “steroids OR 
glucocorticoids OR prednisone OR prednisolone AND COPD OR chronic obstructive pulmonary disease AND exacerbation,” and was 
filtered by RCT and Humans. “Best Match” filter was selected and the de Jong article2 cited above was again included in the results. 
When the “Similar Articles” feature was used, no further citations were found. 
A total of three relevant studies specifically comparing IV to oral glucocorticoids were found. A prospective, single-blind study 
conducted by Ceviker and Sayiner compared a 7-day 32mg/day oral methylprednisolone (MP) course with a 4-day course of 1mg/kg 
four times daily IV MP followed by 3 days of 0.5mg/kg four times daily IV MP.3 The authors showed the two courses did not differ in 
the number of deaths or recurrent exacerbations, but the study was limited with regards to its study population. Only 38 patients 
were studied, 18 receiving oral therapy and 20 receiving IV, which limits the generalizability of the study and allows for selection bias 
to distort the outcome because so few of the population of people with COPD were studied. Another limitation is that the two 
groups did not receive equivalent doses of MP: the oral dosing was considered low dose, while the IV dosing was considered high 
dose. The oral dose was similar to the treatment protocol defined by GOLD, which is 40mg prednisone per day for 5 days.1 The IV 
dose was considered high dose because it was weight-based and delivered more mg of glucocorticoid per day compared to the fixed 
oral dose. 
In a retrospective cohort study performed by Lindenauer et al. of 79,985 patients with COPD exacerbation, the researchers looked at 
treatment failure as defined by requiring mechanical ventilation after the second hospital day, death during hospitalization, or a 
readmission for COPD within 30 days of discharge.4 Patients received some sort of IV glucocorticoid therapy (N=73,765), and were 
compared to 6,220 patients who received oral therapy. Although an enormous number of patients from all over the United States 
were analyzed in this study, the SORT level of evidence was still only 2 because it was a retrospective study.5 One limitation was the 
lack of standardized treatments for the two groups as ranges of prednisone equivalents were defined for each group rather than a 
defined dose of a specific glucocorticoid. This means there was variation of dosing between the groups as well as within the groups. 
Another limitation was that patients were only reviewed for 30 days post discharge rather than 90 days as seen in the other two 
studies. 
de Jong et al conducted the third study, a randomized-controlled trial directly comparing IV and oral glucocorticoids.2 The article was 
considered to be the highest quality article found and was chosen for appraisal. 
Critical Appraisal 
The study performed by de Jong et al. was a double-blind, double-dummy comparing 103 patients receiving a 5-day course of 60mg 
oral prednisolone daily to 107 patients receiving a 5-day course of 60mg IV prednisolone daily. Of the 210 patients analyzed, 29 
missed follow-up visits (13 of the IV treatment and 16 of the oral treatment) because of early or late treatment failure, or didn’t 
show up. In the per-protocol analysis, 8 IV patients and 9 oral patients were excluded because they withdrew consent or met one of 
the exclusion criteria. An intention-to-treat analysis was used to assess the primary outcomes, which mitigated the effect of patients 
dropping out. After the initial 5-day course, all patients received 30mg prednisolone daily, which was then tapered. During the 5-day 
course all patients received nebulized ipratropium-albuterol with oral amoxicillin/clavulanate. The double-dummy method was a 
particular strength of this study because the other studies mentioned had the patients receiving either an IV or oral drug rather than 
both. An intention-to-treat analysis was used to analyze the data, and a treatment failure percent difference of less than 15% was 
used to determine non-inferiority. Based on the description of the study in the methods section it appears that the patients in both 
were treated as equally as possible. The patient characteristic table showed randomization was successful and our patient was 
similar to the patients included based on Table 1 of the study. 
The inclusion criteria of this study were age>40 years, had at least a 10-pack-year history of smoking, and evidence of airflow 
limitation (FEV1/FVC<70% and FEV1<80% predicted). An exacerbation was defined as increased breathlessness with two of the 
following for >24 hours: increased cough frequency or severity, increased sputum volume or purulence, and increased wheeze. 
Patients were excluded if arterial pH<7.26 or PaCO2>70mmHg, had a history of asthma, participated in previous study within 4 
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weeks of admission, already randomized to this study, clinical findings on chest x-ray other than COPD, hypersensitivity to 
prednisolone, or were totally noncompliant. JB would have been excluded from the study because his pH was less than 7.26, but he 
met all the other criteria. Although his pH was low, the study is still important to consider in clinical decision making because the 
patient was stable enough for the general medicine floor. The primary outcome studied was treatment failure, defined as death 
from any cause, admission to ICU, readmission because of COPD, or intensification of pharmacological treatment. Intensification of 
pharmacological treatment was use of theophylline, open-label corticosteroids, or antibiotics. Patients were followed for three 
months after initial hospital treatment. Three months was adequate follow up because the steroid treatment is meant to manage 
the patient’s current exacerbation, not to treat COPD long-term. 
Bias was mitigated as much as possible, but one problem for generalizing this study to the clinical scenario above was that the study 
occurred in the Netherlands. The study also makes no mention of the ethnicities included in the population, which also prohibits the 
generalizability to this patient’s urban population. More time for follow-up would also strengthen the study as COPD is a chronic 
disease and exacerbations can occur any time over the patient’s life. Nonetheless, based on the study design and number of patients 
in the study a SORT level of evidence of 1 is achieved. 
Results of the study showed no significant differences in treatment failure rate as the lower and upper bounds of the 95% 
confidence interval included 0%, therefore the criteria for noninferiority were met when comparing oral to IV prednisolone therapy. 
61.7% of IV therapy patients experienced a treatment failure while 56.3% of oral therapy patients experienced treatment failure. 
The number of deaths was 5 in the IV group and 2 in the oral group, while hospital readmissions numbered 13 for the IV group and 
11 in the oral group. The number needed to treat in this study was 18.5 using oral therapy, but the utility of this number is limited. 
The study was not designed to see if oral therapy provided better outcomes, but rather to see if oral therapy provided similar 
outcomes. A number needed to treat would be useful in studies where the authors were trying to prove better outcomes. 
Clinical Application 
The de Jong study showed that oral prednisolone was not inferior to IV prednisolone in managing COPD 
exacerbations with regards to mortality and subsequent hospitalizations. The conclusion of the article is supported 
by the evidence provided in the results section and is relevant to the case above even though the patient would 
have been excluded because of the severity of his disease. Once the patient was stable enough for the floor, he 
expressed wishes to be treated to the full extent possible and had plans to go home. Following the standard of 
care, he was given oral corticosteroids. The additional course of IV steroids provided no relief. He was given 
morphine to decrease his dyspnea and was sent to hospice after consultation with his family. The study is relevant 
to this patient because he received both oral and IV corticosteroids for his COPD exacerbation. Although the study 
occurred in the Netherlands, the strengths of the study make generalizing the study less hazardous to this patient’s 
clinical scenario. 
It could be argued that by treating the patient in the clinical situation above with IV prednisone after oral 
prednisone a disservice was done to him because redundant therapy was performed based on the conclusion that 
oral glucocorticoid therapy is equivalent to IV therapy. More money was spent on unnecessary treatment and the 
patient was exposed to potential infection by giving him IV therapy. 
Learning points: 
1. Oral glucocorticoid therapy is equivalent to IV therapy in COPD exacerbation. 
2. Evidence-based medicine requires use of multiple well-designed studies to support and guide decision-
making. 
3. Managing COPD is difficult and limiting outside disease process such as infection should be considered when 
deciding therapy. 
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